SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-013566
Filing Date
2024-02-12
Accepted
2024-02-12 07:30:29
Documents
76
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q acst-20231231.htm   iXBRL 10-Q 1598918
2 EX-31.1 acst-ex31_1.htm EX-31.1 14295
3 EX-31.2 acst-ex31_2.htm EX-31.2 13540
4 EX-32.1 acst-ex32_1.htm EX-32.1 8895
5 EX-32.2 acst-ex32_2.htm EX-32.2 9442
6 GRAPHIC img180445768_0.jpg GRAPHIC 53024
7 GRAPHIC img180445768_1.jpg GRAPHIC 19086
8 GRAPHIC img180445768_2.jpg GRAPHIC 101322
9 GRAPHIC img180445768_3.jpg GRAPHIC 14782
10 GRAPHIC img180445768_4.jpg GRAPHIC 68654
11 GRAPHIC img180445768_5.jpg GRAPHIC 64097
12 GRAPHIC img180445768_6.jpg GRAPHIC 41281
  Complete submission text file 0000950170-24-013566.txt   7184415

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acst-20231231.xsd EX-101.SCH 1089097
77 EXTRACTED XBRL INSTANCE DOCUMENT acst-20231231_htm.xml XML 850473
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-649-9272
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-35776 | Film No.: 24617379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)